Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD2 antibody variable domain is fused to CH1 and the other scFv from an anti-TCR (Vβ8) antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can activate T cells. It is designed for the research of Tumors therapy.